Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma
Simultaneous early monitoring of ctDNA and TCR dynamics reveals key determinants of ICB outcomes in R/M HNSCC. The transient nature of TCR diversification emphasizes the importance of precise sample timing to guide early therapeutic decisions and improve patient outcomes.
Authors
- Lillian L. Siu (ORCID: https://orcid.org/0000-0002-3500-0540)
- Marian Tang (ORCID: https://orcid.org/0009-0000-9899-7782)
- Stephanie Pedersen (ORCID: https://orcid.org/0000-0002-4525-371X)
- Shirin Soleimani (ORCID: https://orcid.org/0000-0002-3027-7057)
- Aaron R. Hansen (ORCID: https://orcid.org/0000-0002-2363-8707)
- Minetta C. Liu (ORCID: https://orcid.org/0000-0002-8206-5232)
- Enrique Sanz‐García (ORCID: https://orcid.org/0000-0002-3119-3832)
- Prabhjit Basra (ORCID: https://orcid.org/0009-0006-0193-6945)
- Sam Felicen (ORCID: https://orcid.org/0009-0000-5500-1930)
- George Laliotis (ORCID: https://orcid.org/0000-0001-9205-8258)
- Michael Krainock (ORCID: https://orcid.org/0000-0003-0081-4584)
- Pamela S. Ohashi (ORCID: https://orcid.org/0000-0003-2915-9317)
- Jenna Eagles (ORCID: https://orcid.org/0009-0008-3622-597X)
- Celeste Yu (ORCID: https://orcid.org/0000-0002-8764-1091)
- Lawson Eng (ORCID: https://orcid.org/0000-0002-4816-8385)
- Scott Victor Bratman (ORCID: https://orcid.org/0000-0001-8610-4908)
- Lisa M. Avery (ORCID: https://orcid.org/0000-0002-8431-5143)
- Trevor J. Pugh (ORCID: https://orcid.org/0000-0002-8073-5888)
- Anna Spreafico (ORCID: https://orcid.org/0000-0002-3034-3042)
- Jeffrey P. Bruce (ORCID: https://orcid.org/0000-0001-5509-9990)
Institutions
- Ontario Institute for Cancer Research (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Natera (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3541
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Genomic Health
- Menarini Silicon Biosystems
- Natera
- Eisai
- Genentech